Ameluz® PDT Phase 3 Trial Meets Primary Endpoint
WOBURN, Mass., Feb. 9, 2026 — Biofrontera Inc. announced positive top-line results from its multicenter Phase 3 clinical trial...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
WOBURN, Mass., Feb. 9, 2026 — Biofrontera Inc. announced positive top-line results from its multicenter Phase 3 clinical trial...
WASHINGTON, D.C., December 11, 2025 — The American Academy of Dermatology Association (AAD) issued a formal statement supporting the...
